NEW YORK, Oct. 2, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in October. RetailInvestorConferences.com The RedChip 15th Annual Fall Small-Cap Conference Regenerative Medicine Foundation 2012 Conference 2012 Stem Cell Meeting on the Mesa, 2nd Annual Investor and Partnering Forum About NeoStem, Inc. NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve … Continue reading →

ZUTPHEN, the Netherlands, October 2, 2012 /PRNewswire/ -- Cryo-Save Group promotes the awareness of cord blood storage and stem cell therapies at several local educational events held throughout Europe. Cryo-Save continues its Cord Blood Awareness Months celebration by sponsoring educational events in the Netherlands, Italy and Spain during the months of October and November. It is events like these that Cryo-Save hopes to bring awareness of and research advancements for the stem cell industry. Stem cells are becoming ever more important in the medical field as a way to treat a broad variety of malignant and non-malignant diseases. The U.S. National Marrow Donor Program sites cord blood as treatment for multiple myeloma, severe aplastic anaemia, beta thalassemia major, SCID and other inherited immune system disorders, and leukaemias and lymphomas. Patients suffering from sickle cell anaemia have been considered cured after being treated with stem cells.[1] Over 4,000 clinical trials using cord blood stem cells are taking place to treat diseases such as cerebral palsy, diabetes and autism with many more potential clinical trials continuing to develop. "Cryo-Saves efforts to inform the medical professionals and community members about advances in regenerative medicine means that patients suffering from diseases treatable with stem … Continue reading →

SAN DIEGO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) to assess the clinical effects of Stemedyne-MSC (Stemedica's human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with a myocardial infarct. The Phase IIa double-blinded randomized clinical trial will study approximately forty (40) patients. All patients will initially receive standard care including percutaneous transluminal coronary angioplasty (PTCA) and stenting and, upon completion, will be randomized to receive Stemedyne-MSC intravenously or placebo. The clinical trial will address the prevalence of cardiovascular disease estimated to carry a global disease burden in excess of $400 billion each year. More than one million patients undergo PTCA and stenting in the Untied States annually; another 800,000 have the procedures each year in Europe. Nabil Dib, M.D., MSc., F.A.C.C., Director of Cardiovascular Research at Mercy Gilbert and Chandler Regional Medical Centers, and an Associate Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy at the University of California, San Diego, will serve as the principal investigator of the FDA-approved … Continue reading →

By Cristina Flores (KUTV) Since 2009, Utah families with autistic children have lobbied hard on Capitol Hill, to convince Utah lawmakers to pass an insurance mandate that would require insurance companies to cover autism treatment. Instead, what those families got was the Utah Medicaid Autism Waiver - a pilot program that will enroll 200 families of autistic children. Mirella Peterson, President of the Utah Autism Coalition said the legislature's solution is "completely inappropriate" on many levels. First, the pilot program will only help 200 families - there are some 18,000 autistic children in Utah she said. Second: Peterson thinks lawmakers will falsely pat themselves on the back for helping autistic parents. Christine Passey will enroll her 4 year-old daughter Skylynn, who currently requires 800 dollar-per-week therapy. The Passey's can't afford that expense all year long, which breaks Christine's heart because therapy clearly helps her daughter. "To be honest I am not thrilled about having to apply to a government program for help for my daughter but she needs the help," she said. The Passeys have health insurance but as is the case with other families, it does not cover autism treatment. 32 States have an insurance mandate for autism treatment … Continue reading →